PharmaNutra signs new distribution agreements in Denmark and Albania

Pharmaforce APS and Alb Global Pharma are the Group’s new partners that will launch the products SiderAL^® Forte and SiderAL^® Folic in Denmark and Albania by the end of 2022.

PharmaNutra S.p.A. is pleased to announce that it has signed two new international distribution agreements for the SiderAL^® range, the food supplements containing Sucrosomial^® Iron that have made the Group an Italian and international leader in the iron therapies market in recent years.

The first agreement, which was concluded with Pharmaforce APS, provides for the distribution of SiderAL^® Forte and SiderAL^® Folic in Denmark, where there is growing interest in oral iron solutions that represent a valid alternative to intravenous treatment, which are far more invasive and are characterised by tolerability and compliance issues, particularly in clinical settings such as gastroenterology and gynaecology.

As far as Albania is concerned, the new partner Alb Global Pharma will commence the distribution of SiderAL^® Forte and SiderAL^® Folic with a view to expanding its product portfolio in the near future and introducing two SiderAL^® products for the paediatric sector as part of a second phase. As a matter of fact, it is estimated that in Albania 23% of women and 11% of men between 15 and 49 years of age have sideropenia (iron-deficiency anaemia), and these rates are as high as 25% in babies and children between 6 months and 4 years of age.

In both settings, the introduction of SiderAL^® supplements and the Sucrosomial^® Technology patented by PharmaNutra can make a difference in the approach to and management of iron deficiency in all those medical disciplines in which the current treatments present difficulties, particularly those associated with tolerability and the absorption of iron, an element that, as is known, is associated with a number of gastrointestinal issues.

“We have developed a truly unique technology, able to make the difference to a global problem, meaning that not only is the international expansion of SiderAL^® now consolidated, but it is also a key factor of our business strategy”, declares PharmaNutra S.p.A. Executive Director, Andrea Lacorte. “It is a fundamental asset that every year allows us to carry out new studies and research to improve and fine-tune further products and technologies, which translates into greater effectiveness, better safety and higher scientific credibility, both in Italy and abroad.”

The conclusion of these recent agreements has increased the PharmaNutra Group’s list of international partners: in 2022, it has already signed 5 new agreements, taking the number of distributors to 45, covering a total of 68 countries, of which 34 in Europe and 34 in non-European countries between Asia, Latin America and Africa.